drugset / Trial / NCT05576272
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open, multicenter phase II/III trial to compare the efficacy and safety of QL1706 and carrilizumab combined with gemcitabine and cisplatin in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Timeline
- Start
- 2022-05-19
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | QL1706 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |